A Phase I Safety and Tolerability Study of Vorinostat in Combination With Sorafenib in Patients With Advanced Solid Tumors, With Exploration of Two Tumor-type Specific Expanded Cohorts at the Recommended Phase 2 Dose
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2013
At a glance
- Drugs Sorafenib (Primary) ; Vorinostat (Primary)
- Indications Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 07 Mar 2008 New trial record.